|
Project |
Method |
Target Indication |
Development Stage |
Partner |
|
SO-001 |
Drug Repositioning |
Taxane Resistance |
Use patent (Japan/PCT) |
– |
|
SO-001-D |
Derivative |
Prostate Cancer (taxane resistance) |
Lead Compound |
Nanjing Medical Univ. |
|
SO-001-D |
Derivative |
Breast Cancer (taxane resistance) |
Lead Compound |
Nanjing Medical Univ. |
|
SO-001-D |
Derivative |
Uterine Cancer (taxane resistance) |
Lead Compound |
Nanjing Medical Univ. |
|
SO-002(ALS) |
Drug Repositioning |
ALS |
Use patent (Japan/PCT) |
|
|
SO-002(ALS)-D |
Derivative |
ALS |
Nanjing Medical Univ. |
|
|
SO-002(FTLD) |
Drug Repositioning |
FTLD |
Use patent (Japan/PCT) |
|
|
SO-002(FTLD)-D |
Derivative |
FTLD |
Nanjing Medical Univ. |
|
|
SO-003 |
Drug Repositioning |
sIBM |
Nanjing Medical Univ. |
|
|
SO-003-D |
Derivative |
sIBM |
Nanjing Medical Univ. |
|
|
Keio University |
Drug Repositioning |
Aging-associated diseases |
in vivo assay |
To Be Scheduled |
|
Tokushima University |
Drug Repositioning |
Rare Cancer |
in vitro assay |
To Be Scheduled |
|
Kanawaza University |
Drug Repositioning |
Immune Checkpoint Inhibitor Adjuvant |
in vitro assay |
To Be Scheduled |
All programs are obtained through the proprietary AI-based technology.